Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Staphylococcus aureus keratitis: clinical characteristics and antibiotic susceptibilities

Poster Details

First Author: C.Hsiao TAIWAN

Co Author(s):                  

Abstract Details


To investigate the antibiotic susceptibility, clinical findings and outcomes of keratitis caused by methicillin-sensitive Staphylococcus aureus (MSSA) versus methicillin-resistant (MRSA) S. aureus.


The patients with culture- proven S. aureus keratitis were seen at Chang Gung Memorial Hospital between January 2006 and December 2010.


Data collected included patient demographics and clinical information. Antibiotic susceptibility was verified by disc diffusion method.


Sixty-seven cases of S. aureus keratitis were identified, including 30 (44.78%) caused by MRSA and 37 (55.22%) caused by MSSA. There was no difference in gender and age in the two groups. All MRSA and MSSA isolates were sensitive to vancomycin and teicoplanin. Eighty-two percent of MRSA isolates were sensitive to sulfamethoxazole/trimethoprim. Among the local factors related to corneal ulcer, pre-existing ocular surface disease was the most common risk factor for both patients with MRSA and MSSA keratitis. There was no significantly difference about the location, infiltration size and presence of hypopyon between MRSA and MSSA corneal ulcer. Fortified topical antibiotic, amikacin (25mg/ cc) with cefazolin (25mg/cc) were most commonly used as the empirical antibiotics in all patients. The rate of modification in the medication was significantly greater in the patients with MRSA infection. No significant difference was found in the rate of surgical intervention, rate of severe complication, time for complete remission and the final visual acuity between these two groups.


All MSSA and MRSA isolates were sensitive to vancomycin and most patients can be treated successfully with fortified topical antibiotics. No significant difference in the clinical outcomes between MRSA and MSSA patients. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.